Skip to main content
Microbiology Spectrum logoLink to Microbiology Spectrum
letter
. 2026 Feb 4;14(3):e02964-25. doi: 10.1128/spectrum.02964-25

An optimized 16S–23S rRNA intergenic spacer region PCR for the detection and identification of Bartonella spp.

Alexander A Dichter 1, Rebecca Kaufmann 1, Luis Solis Cayo 2,3, Pablo Tsukayama 3, Volkhard A J Kempf 1,✉
Editor: Irene Burckhardt4
PMCID: PMC12955397  PMID: 41636488

LETTER

The emerging genus Bartonella comprises 60 species with unknown medical relevance (National Center for Biotechnology Information, Taxonomy Browser, 5 December 2025 [1]). Some species are human pathogenic (e.g., B. henselae: cat scratch disease, bacillary angiomatosis; B. quintana: trench fever, endocarditis; and B. bacilliformis: Carrion’s disease); other species (e.g., B. alsatica: endocarditis and B. grahamii: lymphadenopathy) are only rarely described to cause human infections (2). Accurate diagnosis of Bartonella infections remains challenging due to unspecific clinical manifestations, difficulties in cultivation, genetic diversity within the genus, and frequent occurrence of low-level bacteremia in infected patients (3). Therefore, because of the fact that serological diagnostics have been developed only for B. henselae, B. quintana (4), and recently for B. bacilliformis (5), PCR-based assays have become indispensable for pathogen detection and differentiation. Pioneer work of Maggi and Breitschwerdt established the 16S–23S rRNA intergenic spacer (ITS) region as a valuable diagnostic target widely used in molecular diagnostics of Bartonella infections. This region is highly variable in sequence and length between Bartonella species and is embedded between conserved flanking regions, allowing the design of universal primers and enabling a reliable discrimination among closely related Bartonella species (6). Despite this great contribution to diagnostics, our results revealed that this PCR protocol with the described ITS primers fails to amplify particular species that were later fully sequenced or discovered because of numerous mismatches to the ITS target sequence (Fig. 1A). This limitation might lead to false-negative results in both clinical and epidemiological studies, ultimately impacting patient management or public health surveillance. Here, we aimed to optimize an ITS-PCR (targeting a sequence of the 16S–23S rRNA ITS) for improved diagnosis of clinically relevant Bartonella species.

Fig 1.

Gel electrophoresis shows DNA amplification of the Bartonella ITS region using two primer sets. Sequence alignments display binding sites with nucleotide mismatches between published primers and new consensus-derived primers.

Primer binding sites and PCR amplification results (agarose gel electrophoresis) targeting the Bartonella ITS region. (A) Previously published primers (6) and (B) primers designed based on the consensus sequence established in this study were used. The consensus sequence of the ITS region and the corresponding primer sequences are shown in the subfigures, with mismatches indicated in red.

Genomic sequences from 16 Bartonella species (Table 1) were aligned using MAFFT v.7.490 (Geneious, Dotmatics, Auckland, New Zealand). Only 16S–23S rRNA ITS sites that were 100% conserved across all aligned sequences were considered for primer construction, covering the major pathogenic and novel emerging species (BsppITS-386s: 5′-GGTTAGAGCGCGCGCTTGATAAGC-3′ [3′ end of the 16S rRNA gene] and BsppITS-824as: 5′-CCTGCTTGCAAAGCAGGTGCTC-3′ [5′ end of the 23S rRNA gene]) generating PCR amplicons between 207 and 438 nucleotides.

TABLE 1.

Bartonella strains used in this study for the development of an optimized 16S–23S intergenic spacer region PCR

Bartonella strains Accession no. of reference genomea PCR amplicon size
B. alsatica IBS 382 (CIP105477) CP058235 367
B. ancashensis A07 CP180576 311
B. bacilliformis KC583 CP000524 255
B. bacilliformis KC584 CP045671 255
B. birtlesii CIP106294 KE007210 407
B. capreoli CIP 106691 CADDZX010000017 207
B. chomelii A828 NZ_JACJIR010000013 219
B. doshiae ATCC 700133 CACVBE010000020 329
B. elizabethae ATCC 49927 NZ_LR134527 438
B. grahamii ATCC 700132 CP001562 352
B. henselae Houston 1 NZ_CP072903 438
B. henselae Marseille NZ_CP072904 438
B. quintana JK31 KL411732 367
B. schoenbuchensis DSM 13525 NZ_CP154603 207
B. tribocorum CIP10476 AM260525 424
B. vinsonii ATCC 51672 CADEAK010000021 406
a

Reference genomes were taken from https://www.ncbi.nlm.nih.gov.

DNA was extracted from Bartonella cultures and 12 bacterial control strains (Table S1). PCR was performed under certified conditions (DIN EN ISO 15189:2024, certificate number D-ML-13102-01-00): initial denaturation (95°C/3 min), followed by 35 cycles (denaturation 94°C/20 s; annealing: 60°C/30 s, elongation: 72°C/40 s, final extension 72°C/1 min). Products were analyzed by agarose gel electrophoresis, demonstrating a robust amplification across all tested strains, including B. bacilliformis and B. ancashensis (Fig. 1B).

In silico, PCR products were aligned using MAFFT to assess sequence variability within the amplified ITS region to evaluate the potential for species-level discrimination. This in silico sequence analysis of the expected amplicons revealed unique DNA sequences except for B. capreoli and B. schoenbuchensis (Table S2), confirmed by Sanger sequencing (data not shown). Specificities of the old and new PCR protocols were evaluated using a broad selection of 12 clinically relevant bacterial strains (Fig. 2A; Table S1), demonstrating no unspecific amplicons between 207 and 438 bp, not even for the four closely related Brucella spp. PCR sensitivities were evaluated by spiking sterile human blood samples with DNA from B. henselae Marseille (final concentrations: 33 ng/µL to 3.3 × 10−6 ng/µL). DNA was extracted using the QIAsymphony DSP Virus/Pathogen Kit (Qiagen, Hilden, Germany) under certified conditions (DIN EN ISO 15189:2024), and the 16S–23S rRNA ITS region was amplified using both the old and new PCR protocol. Data revealed that both PCRs have a comparable sensitivity (3.3 × 10−3 ng/µL, Fig. 2B). As the 16S–23S rRNA ITS region is present twice in the genomes of Bartonella spp., it might represent a PCR target resulting in more sensitive PCRs compared to PCR targets with only one copy (16S-rDNA, ftsZ, gltA, groEL, ribC, and rpoB). This speculation, however, has not been addressed experimentally.

Fig 2.

Gel electrophoresis images comparing specificity and sensitivity of two PCR primer sets for B. henselae detection, showing band patterns for various bacterial controls and serial dilutions of target DNA in blood samples.

Determination of (A) specificity and (B) sensitivity of the 16S–23S rRNA intergenic spacer region PCRs. (A) Control bacteria (see Table S1) were grown under standard laboratory conditions. Positive control: B. henselae Marseille, negative control: aqua dest. (dH2O). (B) Sterile human blood samples were spiked with DNA from B. henselae Marseille at the indicated final concentrations (ranging from 33 to 3.3 × 10−6 ng/µL). Negative control: aqua dest. (dH2O). Left panels: Primers 321s/983as (described in reference 6). Right panels: Primers BsppITS-386s/BsppITS-824as (described in this study).

Our study underscores the importance of periodically re-evaluating diagnostic primers in PCR-based diagnostic approaches as new bacterial species are identified. In regions where Bartonella-related illnesses are endemic, implementation of the optimized ITS primers could improve diagnostic accuracy, facilitate timely treatment, and support more reliable molecular epidemiology.

ACKNOWLEDGMENTS

The work of V.A.J.K. was supported by the LOEWE Center DRUID ([Novel Drug Targets against Poverty-Related and Neglected Tropical Infectious Diseases [Project C2]) and the Robert Koch-Institute, Berlin, Germany (Bartonella Consiliary Laboratory, 1369-354). The work of P.T. was supported by Prociencia Perú (grant PE501096118-2025). Funding parties did not influence data analysis, data interpretation, or the writing of the manuscript.

All authors contributed to the study conception and design. Collection of bacterial strains was performed by A.A.D., L.S.C., P.T., and V.A.J.K. Experimental design was done by V.A.J.K. Experimental and routine diagnostic assays were done by A.A.D. and R.K. Manuscript writing was done by A.A.D. and V.A.J.K. All authors read and approved the final manuscript.

During the preparation of this work, the authors used ChatGPT AI in order to improve language and grammar. After using this tool/service, the authors reviewed and edited the content as needed and took full responsibility for the content of the publication.

Contributor Information

Volkhard A. J. Kempf, Email: volkhard.kempf@ukffm.de.

Irene Burckhardt, University of Heidelberg, Heidelberg, Germany.

DATA AVAILABILITY

All data are provided within the article and the supplemental material.

SUPPLEMENTAL MATERIAL

The following material is available online at https://doi.org/10.1128/spectrum.02964-25.

Supplemental tables. spectrum.02964-25-s0001.pdf.

Tables S1 and S2.

DOI: 10.1128/spectrum.02964-25.SuF1

ASM does not own the copyrights to Supplemental Material that may be linked to, or accessed through, an article. The authors have granted ASM a non-exclusive, world-wide license to publish the Supplemental Material files. Please contact the corresponding author directly for reuse.

REFERENCES

  • 1. National Center for Biotechnology Information (NCBI) . 2026. Bartonellaceae (Taxonomy ID: 772) and Bartonella (Taxonomy ID: 773). NCBI Taxonomy. https://www.ncbi.nlm.nih.gov/datasets/taxonomy/tree/?taxon=772,773
  • 2. Krügel M, Król N, Kempf VAJ, Pfeffer M, Obiegala A. 2022. Emerging rodent-associated Bartonella: a threat for human health? Parasit Vectors 15:113. doi: 10.1186/s13071-022-05162-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Maggi RG, Richardson T, Breitschwerdt EB, Miller JC. 2020. Development and validation of a droplet digital PCR assay for the detection and quantification of Bartonella species within human clinical samples. J Microbiol Methods 176:106022. doi: 10.1016/j.mimet.2020.106022 [DOI] [PubMed] [Google Scholar]
  • 4. Centers of Disease Control and Prevention (CDC) . 1999. Serodiagnosis of emerging infectious diseases: Bartonella and Ehrlichia infections (course manual). Workshop February 1-4, 1999. Georgia Public Health Laboratory, Atlanta, Georgia, USA. [Google Scholar]
  • 5. Dichter AA, Schultze TG, Wenigmann A, Ballhorn W, Latz A, Schlüfter E, Ventosilla P, Guerra Allison H, Ugarte-Gil C, Tsukayama P, Kempf VAJ. 2021. Identification of immunodominant Bartonella bacilliformis proteins: a combined in-silico and serology approach. Lancet Microbe 2:e685–e694. doi: 10.1016/S2666-5247(21)00184-1 [DOI] [PubMed] [Google Scholar]
  • 6. Maggi RG, Breitschwerdt EB. 2005. Potential limitations of the 16S-23S rRNA intergenic region for molecular detection of Bartonella species. J Clin Microbiol 43:1171–1176. doi: 10.1128/JCM.43.3.1171-1176.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental tables. spectrum.02964-25-s0001.pdf.

Tables S1 and S2.

DOI: 10.1128/spectrum.02964-25.SuF1

Data Availability Statement

All data are provided within the article and the supplemental material.


Articles from Microbiology Spectrum are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES